Key Insights Revolution Medicines will host its Annual General Meeting on 20th of June Total pay for CEO Mark Goldsmith...
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. Details of the company’s participation are as follows: Goldman Sachs 45th Annual Gl
Insights into RVMD's Financial Health and Future Directions